21,125 Boston Scientific Corporation $BSX Shares Sold by Nemes Rush Group LLC

Nemes Rush Group LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 94.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,144 shares of the medical equipment provider’s stock after selling 21,125 shares during the quarter. Nemes Rush Group LLC’s holdings in Boston Scientific were worth $50,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific during the 1st quarter valued at about $28,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Boston Scientific in the 1st quarter valued at about $32,000. Measured Wealth Private Client Group LLC lifted its holdings in shares of Boston Scientific by 244.9% in the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 387 shares during the last quarter. Kelleher Financial Advisors purchased a new position in Boston Scientific in the second quarter worth about $25,000. Finally, Nvwm LLC grew its position in Boston Scientific by 526.2% in the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 542 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BSX shares. Canaccord Genuity Group reduced their price objective on Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a research note on Thursday, October 29th. Citigroup lowered their price objective on Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, October 29th. Oppenheimer cut Boston Scientific from an “outperform” rating to a “market perform” rating in a report on Thursday, October 29th. Stifel Nicolaus cut their target price on Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Finally, Evercore cut their target price on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Price Performance

BSX stock opened at $44.67 on Wednesday. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average price of $44.19 and a 200 day moving average price of $55.23. The stock has a market cap of $64.74 billion, a PE ratio of 18.93, a P/E/G ratio of 1.30 and a beta of 0.60.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the prior year, the firm posted $0.75 EPS. The firm’s revenue was up 1.4% compared to the same quarter last year. Equities research analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.